Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trepibutone SCHEMBL29441541 | 0.87 | TSHR (0.61) | KMT2AMEN1HTTTSHRHSD17B10 | |
| Trepibutone SCHEMBL25039 | 0.87 | TSHR (0.61) | KMT2AMEN1HTTTSHRHSD17B10 | |
| SCHEMBL11686404 | 0.86 | TSHR (0.47) | KMT2AMEN1TSHRHSD17B10CYP3A4 | |
| SCHEMBL11684059 | 0.84 | HMGCR (0.51) | KMT2AMEN1HTTTSHRHSD17B10 | |
| SCHEMBL11683833 | 0.80 | TSHR (0.51) | TSHRHSD17B10CYP3A4DGAT1LMNA | |
| SCHEMBL11683269 | 0.79 | TSHR (0.51) | KMT2AMEN1HTTTSHRHSD17B10 | |
| SCHEMBL8214127 | 0.78 | TAS1R3 (0.55) | KMT2AMEN1HTTTSHRHSD17B10 | |
| SCHEMBL11686088 | 0.78 | TSHR (0.72) | HTTTSHRHSD17B10CYP3A4LMNA | |
| SCHEMBL4264820 | 0.77 | TSHR (0.58) | KMT2AMEN1TSHRHSD17B10CYP2C19 | |
| SCHEMBL11833308 | 0.76 | HMGCR (0.49) | KMT2AMEN1HTTTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3943169-A | DIURETIC, SPASMOLYTIC | TAKEDA CHEMICAL INDUSTRIES, LTD (JA) | 1976-03-09 | — | — | US | claimed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-4029699-A | CHOLERETIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-06-14 | — | — | US | disclosed |
| US-4017517-A | SPASMOLYTIC, CHOLERETIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-04-12 | — | — | US | disclosed |
| US-3943169-A | DIURETIC, SPASMOLYTIC | TAKEDA CHEMICAL INDUSTRIES, LTD (JA) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | KMT2A 410/4885MEN1 4668/4885HTT 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.